{
  "id": 179714,
  "title": "Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch",
  "url": "https://urgent.news/2026/08/05/earnings-roundup-gileads-uncertain-future-pfizers-crossroads-and",
  "topic": "world",
  "section": "World",
  "published": "2026-08-05T15:00:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/pfizer-merck-gilead-earnings-2q-2026-analysis/827029/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}